LONGEVA.

Bimagrumab: adverse events and evidence limits

A 48-week intravenous bimagrumab trial in type 2 diabetes with overweight or obesity reported diarrhea and muscle spasms. Serious events occurred in both arms; pancreatitis occurred in the bimagrumab arm. [1]

Occurrence does not establish causation. This cohort and preparation do not establish another product’s risks. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
DiarrheaAdults with type 2 diabetes and overweight or obesity, intravenous, 48 weeksReported; no frequency given[1]
Muscle spasmsThe same participantsReported; no frequency given[1]
Pancreatitis (serious event)The bimagrumab arm of the same trialOccurred in the bimagrumab arm; serious events occurred in both arms; occurrence does not establish causation[1]

References

  1. Steven B Heymsfield et al. (2021). Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial https://doi.org/10.1001/jamanetworkopen.2020.33457.